65 Participants Needed

Metreleptin for Partial Lipodystrophy

(METRE-PL Trial)

Recruiting at 55 trial locations
JB
Overseen ByJanet Boylan
Age: Any Age
Sex: Any
Trial Phase: Phase 3
Sponsor: Amryt Pharma
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it mentions that patients should be on optimized stable therapy. This suggests you may need to continue your current treatment.

What data supports the effectiveness of the drug metreleptin for partial lipodystrophy?

Research shows that metreleptin helps improve eating behavior in lipodystrophy patients by increasing feelings of fullness and reducing hunger, and these benefits last for a long time.12345

How is the drug metreleptin unique for treating partial lipodystrophy?

Metreleptin is unique because it is specifically designed to replace leptin, a hormone that helps regulate fat and sugar levels in the body, which is often deficient in people with lipodystrophy. Unlike other treatments, it directly addresses the underlying hormone imbalance rather than just managing symptoms like high blood sugar or cholesterol.13567

What is the purpose of this trial?

This trial tests the safety and effectiveness of daily injections of metreleptin for people with Partial Lipodystrophy. The treatment aims to replace a missing hormone to help their bodies manage fat and sugar levels better. Metreleptin is approved by the United States Food and Drug Administration for the treatment of generalized forms of lipodystrophy and has shown improvement in many patients.

Eligibility Criteria

This trial is for individuals with a condition called Partial Lipodystrophy, specifically those diagnosed with Familial Partial Lipodystrophy (FPLD). It's not open to people who have already been treated with metreleptin.

Inclusion Criteria

I have been diagnosed with Familial Partial Lipodystrophy.

Exclusion Criteria

I have been treated with metreleptin before.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive daily subcutaneous metreleptin or placebo for 12 months

12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • metreleptin
  • Placebo
Trial Overview The study is testing the safety and effectiveness of a daily injection of a drug called metreleptin compared to a placebo. This is done in a controlled way where neither the participants nor the researchers know who gets the real treatment or placebo.
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: metreleptinActive Control1 Intervention
Metreleptin \[Recombinant-methionyl human Leptin; r-metHuLeptin\] for daily injection is a sterile, white, solid lyophilised cake
Group II: placeboPlacebo Group1 Intervention
Placebo for daily injection is a sterile, white, solid lyophilised cake

Find a Clinic Near You

Who Is Running the Clinical Trial?

Amryt Pharma

Lead Sponsor

Trials
9
Recruited
1,000+

Findings from Research

In a study involving patients with partial lipodystrophy, metreleptin treatment led to significant improvements in glycemic control, with reductions in HbA1c by 0.6% and fasting triglycerides by 20.8% after 12 months.
Metreleptin was well tolerated, with common side effects including abdominal pain and hypoglycemia, but no unexpected safety issues, indicating it is a safe option for managing metabolic complications in these patients.
Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy.Oral, EA., Gorden, P., Cochran, E., et al.[2022]
In a study of 47 patients with lipodystrophy treated with metreleptin, significant improvements in metabolic outcomes were observed in those with generalized lipodystrophy (GLD), including a notable decrease in glycated hemoglobin (HbA1c) and fasting triglyceride levels after one year of treatment.
While some patients with partial lipodystrophy (PLD) showed initial improvements in triglyceride levels, the overall efficacy of metreleptin in this group was less clear, indicating a need for further clarification on its therapeutic use for PLD.
Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.Mosbah, H., Vantyghem, MC., Nobécourt, E., et al.[2022]
In a study of 5 female lipodystrophy patients treated with metreleptin for over 150 weeks, significant improvements in eating behavior were observed, including a marked decrease in hunger and an increase in feelings of satiety after meals.
The long-term treatment resulted in sustained effects, with hunger ratings dropping significantly and measures of cognitive restraint and desire to eat also improving, indicating that metreleptin can effectively regulate appetite over an extended period.
Beneficial effects of leptin substitution on impaired eating behavior in lipodystrophy are sustained beyond 150 weeks of treatment.Püschel, J., Miehle, K., Müller, K., et al.[2020]

References

Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. [2022]
Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network. [2022]
Beneficial effects of leptin substitution on impaired eating behavior in lipodystrophy are sustained beyond 150 weeks of treatment. [2020]
Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis. [2022]
Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. [2023]
Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use. [2021]
Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security